Canmab is a group of medicines which belongs to anti neoplastics medication. Canmab is a chemotherapy drug, the main ingredient which is used as transtuzumab. It is recommended that Canmab be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.
Canmab INJECTION WORK
Different type of breast cancer cells have a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast. Canmab acts by adhere itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals, Canmab can slow or inhibit the growth of the breast cancer and the drug is an immune targeted therapy. In addition to inhibiting HER2 receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.
The injection Canmab should not mix with other drugs and do not administer as an intravenous push or bolus.
Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine
Adjuvant treatment, breast cancer : The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:
During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:
Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV( intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Canmab dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks. The injection given as a single agent within three weeks following completion of multi-modality,
anthracycline-based chemotherapy regimens: For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion. Adjuvant treatment stretching beyond one year is not recommended.
Metastatic Treatment, Breast Cancer: Canmab administrated alone or in combination with paclitaxel, at an starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.
Metastatic Gastric Cancer: Canmab administrated at an starting dose of 8 mg/kg as a 90 minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.
Embryo fetal damage
Canmab is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment
Patient getting Canmab injection have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinue
Some serious fatal cases of pulmonary toxicity occur during Canmab treatment.
During Canmab treatment some life threatening infusion reactions are produced. In serious infusion reactions, Stop the Canmab treatment permanently. Patient should be treated with premedication before starting the infusion to overcome the such problem, During Canmab treatment.use with Caution.
Therapy induced neutropenia
Higher incidence of neutropenia occurs during Canmab treatment.
In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals. Do not take anthracycline treatment for 7 months after stopping the Canmab treatment. Canmab interaction with anthracycline after ending of Canmab treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.
Normally, if you are pregnant and administrating Canmab injection, one of your greatest worry will be for your unborn child. Because, during pregnancy this cancer medicine may be harmful for your baby. So, if this drug is used during pregnancy, or if the patient becomes pregnant while taking this medicine, the patient should be advice about the hidden hazard to a fetus. You should tell about your pregnancy to your doctor. Your pharmacist must understand your condition in order to check your health, and then your baby will be protected from infection soon after birth. You can also discuss with your doctor about birth control methods that will work for you.
Probably no contraindicated occurs. The patients are contraindicated to the component present in the Canmab, Hence Hypersensitivity reactions are occurs.
The drug Missing doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.
Common side effects:
Redness at injection site (IV)
Mild skin rash
Serious side effects:
Sudden unexplained weight gain
Easy bruising or bleeding
Fast or pounding heartbeat
Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Canmab diluted bag at 2℃ to 8℃ for 24 hours.